Topical sirolimus therapy for epidermal nevus with features of acanthosis nigricans

Melissa Dodds; Sheilagh Maguiness

doi:10.1111/pde.13833

Topical sirolimus therapy for epidermal nevus with features of acanthosis nigricans

Melissa Dodds, Sheilagh Maguiness

Dermatology

Research output: Contribution to journal › Article

1 Scopus citations

Abstract

We present a 4-year-old developmentally appropriate boy with short stature and widespread expanding epidermal nevus with features of acanthosis nigricans. He was found to have a mosaic mutation in FGFR3, the R248C variant. Despite several therapies, he continued to have growth, fissuring, and bleeding of the affected skin. Ultimately, topical sirolimus was attempted and found to improve thickness and overall symptoms.

Original language	English (US)
Pages (from-to)	554-555
Number of pages	2
Journal	Pediatric Dermatology
Volume	36
Issue number	4
DOIs	https://doi.org/10.1111/pde.13833
State	Published - Jul 1 2019

Keywords

FGFR3
acanthosis nigricans
epidermal nevus
topical sirolimus

PubMed: MeSH publication types

Journal Article
Case Reports

Access

10.1111/pde.13833

Fingerprint Dive into the research topics of 'Topical sirolimus therapy for epidermal nevus with features of acanthosis nigricans'. Together they form a unique fingerprint.

Cite this

Dodds, M., & Maguiness, S. (2019). Topical sirolimus therapy for epidermal nevus with features of acanthosis nigricans. Pediatric Dermatology, 36(4), 554-555. https://doi.org/10.1111/pde.13833

@article{7c8ae4cab165432d9b97909cc5b3620b,

title = "Topical sirolimus therapy for epidermal nevus with features of acanthosis nigricans",

abstract = "We present a 4-year-old developmentally appropriate boy with short stature and widespread expanding epidermal nevus with features of acanthosis nigricans. He was found to have a mosaic mutation in FGFR3, the R248C variant. Despite several therapies, he continued to have growth, fissuring, and bleeding of the affected skin. Ultimately, topical sirolimus was attempted and found to improve thickness and overall symptoms.",

keywords = "FGFR3, acanthosis nigricans, epidermal nevus, topical sirolimus",

author = "Melissa Dodds and Sheilagh Maguiness",

year = "2019",

month = jul,

day = "1",

doi = "10.1111/pde.13833",

language = "English (US)",

volume = "36",

pages = "554--555",

journal = "Pediatric Dermatology",

issn = "0736-8046",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Topical sirolimus therapy for epidermal nevus with features of acanthosis nigricans

AU - Dodds, Melissa

AU - Maguiness, Sheilagh

PY - 2019/7/1

Y1 - 2019/7/1

N2 - We present a 4-year-old developmentally appropriate boy with short stature and widespread expanding epidermal nevus with features of acanthosis nigricans. He was found to have a mosaic mutation in FGFR3, the R248C variant. Despite several therapies, he continued to have growth, fissuring, and bleeding of the affected skin. Ultimately, topical sirolimus was attempted and found to improve thickness and overall symptoms.

AB - We present a 4-year-old developmentally appropriate boy with short stature and widespread expanding epidermal nevus with features of acanthosis nigricans. He was found to have a mosaic mutation in FGFR3, the R248C variant. Despite several therapies, he continued to have growth, fissuring, and bleeding of the affected skin. Ultimately, topical sirolimus was attempted and found to improve thickness and overall symptoms.

KW - FGFR3

KW - acanthosis nigricans

KW - epidermal nevus

KW - topical sirolimus

UR - http://www.scopus.com/inward/record.url?scp=85064476439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064476439&partnerID=8YFLogxK

U2 - 10.1111/pde.13833

DO - 10.1111/pde.13833

M3 - Article

C2 - 30983034

AN - SCOPUS:85064476439

VL - 36

SP - 554

EP - 555

JO - Pediatric Dermatology

JF - Pediatric Dermatology

SN - 0736-8046

IS - 4

ER -